Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30785325 | 0.99 | ROCK2 (0.57) | ROCK2EPHX2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL31338586 | 0.99 | ROCK2 (0.57) | ROCK2EPHX2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21331820 | 0.91 | ROCK2 (0.64) | ROCK2EPHX2 | |
| SCHEMBL29548021 | 0.90 | ROCK2 (0.44) | ROCK2CYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL30788622 | 0.89 | ROCK2 (0.62) | ROCK2EPHX2 | |
| SCHEMBL30714841 | 0.85 | ROCK2 (0.58) | ROCK2EPHX2 | |
| SCHEMBL30956271 | 0.85 | ROCK2 (0.58) | ROCK2 | |
| SCHEMBL19712320 | 0.85 | ROCK2 (0.44) | ROCK2 | |
| SCHEMBL25338156 | 0.82 | ROCK2 (0.55) | ROCK2 | |
| SCHEMBL30615146 | 0.81 | ROCK2 (0.54) | ROCK2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 621 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745179-A1 | METHOD FOR PRODUCING ARYLAMINE POLYMER | Resonac Corporation (JP) | 2026-05-20 | — | — | EP | claimed |
| US-20260125395-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2026-05-07 | — | — | US | claimed |
| CN-113999249-B | Methods for preparing tricyclic PI3K inhibitor compounds and methods of treating cancer using the same | 基因泰克公司 | 2025-03-25 | — | — | CN | claimed |
| WO-2025013810-A1 | METHOD FOR PRODUCING ARYLAMINE POLYMER | 株式会社レゾナック | 2025-01-16 | — | — | WO | claimed |
| CN-113999240-B | Conjugated condensed ring macrocyclic material containing hetero atoms, and preparation method and application thereof | 复旦大学 | 2023-09-05 | — | — | CN | claimed |
| CN-114409672-B | Conjugated macrocyclic material based on benzodithiophene, and preparation method and application thereof | 复旦大学 | 2023-09-05 | — | — | CN | claimed |
| US-20230242550-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | GENENTECH, INC. | 2023-08-03 | — | — | US | claimed |
| EP-4161904-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF TOLVAPTAN AND ITS DERIVATIVES | Cambrex Profarmaco Milano S.r.l. (IT) | 2023-04-12 | — | — | EP | claimed |
| EP-4746662-A1 | ORGANIC ELECTRONICS MATERIAL, ORGANIC LAYER, AND ORGANIC ELECTRONICS ELEMENT | Resonac Corporation (JP) | 2026-05-20 | — | — | EP | disclosed |
| EP-4745179-A1 | METHOD FOR PRODUCING ARYLAMINE POLYMER | Resonac Corporation (JP) | 2026-05-20 | — | — | EP | disclosed |
| CN-122070286-A | DNA polymerase theta inhibitor and application thereof | 上海湃隆生物科技有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12630510-B2 | EP2 antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-4739669-A1 | SODIUM CHANNEL BLOCKERS | Novartis AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| CN-122010981-A | GLP-1 receptor agonism/GLP-1 secretagogue double-target compound | 仁奎医药科技(北京)有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2015155197-A1 | NOVEL MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-15 | — | — | WO | disclosed |
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20150005279-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-8846935-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, LCK | ROCK2 135/4885EPHX2 2622/4885CYP1A2 637/4885 |
| US-20130053383-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | ROCK2 1949/4885EPHX2 2881/4885CYP1A2 16/4885 |
| US-20260125395-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | PIK3C2B, PIK3C2A, PIK3CA | ROCK2 321/4885EPHX2 2058/4885CYP1A2 984/4885 |
| US-20150005279-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | ROCK2 1030/4885EPHX2 2368/4885CYP1A2 1415/4885 |
| US-20230242550-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | PIK3CA, PIK3CD, PIK3CB | ROCK2 406/4885EPHX2 1909/4885CYP1A2 1595/4885 |
| US-12630510-B2 | EP2 antagonist | PTGER2, PTGER1, PTGER4 | ROCK2 536/4885EPHX2 345/4885CYP1A2 423/4885 |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | CHRM1, CHRM4, CHRM2 | ROCK2 1952/4885EPHX2 3212/4885CYP1A2 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.